微波热疗联合放化疗治疗进展期胃癌的临床疗效初步观察

doi:10.3760/cma.j.cn113030-20200318-00119

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To preliminarily observe the clinical efficacy of microwave hyperthermia combined with intensity-modulated radiotherapy (IMRT) and chemotherapy for patients with locally advanced gastric cancer. Methods Forty patients who could not been operated or refused operation were enrolled in this clinical trial, who were confirmed as locally advanced proximal or distal gastric cancer by gastroscopy pathology and imaging. Radiotherapy was delivered by IMRT technology for 5 times per week with a total dose of 46 to 56Gy (median dose of 50Gy) in 25 to 28 fractions. Synchronous hyperthermia was given at 42 to 44℃ twice a week, 45 min/time. S-1 or capecitabine-based synchronous chemotherapy was performed, d1-14/3 weeks. The symptom remission rate, adverse reactions, objective remission rate (complete and partial remission) and survival were observed. Results A total of 40 patients, aged between 56 and 83 years (median age of 71 years), were enrolled in this study. The male-to-female ratio was 7:1. Among them, 38 cases (95%) showed symptom remission. The most common adverse reactions were grade 1-2 gastrointestinal reactions and leukopenia. The objective remission rate was 87.5%, the 2-year progression-free survival and overall survival rates were 68.6% and 70.5%, respectively. Conclusion Preliminary findings demonstrate that microwave hyperthermia combined with chemoradiotherapy achieve satisfactory outcomes and yield tolerable toxicity in patients with locally advanced gastric cancer.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Qi Qing
	Lu Yongchang
	Huo Zhongchao
	Wang Li
	Su Ying
	He Xiaolei
	Li Zhijia
	Wang Wenling
	Lyu Linlin
	Zhou Yongle
	Xu Fei
	Zhao Liwei

Key words： Gastric neoplasm/hyperthermia Gastric neoplasm/chemoradiotherapy Treatment outcome

Received: 18 March 2020

Fund:Wu Jieping Medical Foundation (320.6750.17057)

Corresponding Authors: Huo Zhongchao,Email:huozhong_chao@126.com

Cite this article:

Qi Qing,Lu Yongchang,Huo Zhongchao et al. Preliminary observation of clinical efficacy of microwave hyperthermia combined with radiochemotherapy for locally advanced gastric cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(4): 368-371.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200318-00119 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I4/368

[1] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28. DOI:10.3760/cma.j.issn.0253-3766.2019.01.008.
Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(1):19-28. DOI:10.3760/cma.j.issn.0253-3766.2019.01.008.
[2] Wang X, Jin J. S-1 ingastric cancer application in radiotherapy[J]. ChinJ Radiat Oncol, 2015, 24(2):204-208. DOI:10.3760/cma.j.issn. 1004-4221.2015.02.024.
[3] Cheng Y, Weng S, Yu L, et al. The role of hyperthermia in the multidisciplinary treatment of malignant tumors[J]. Integr Cancer Ther, 2019, 18:1534735419876345. DOI:10.1177/1534735419876345.
[4] Issels RD. Hyperthermia adds to chemotherapy[J]. Eur J Cancer, 2008, 44(17):2546-2554. DOI:10.1016/j.ejca.2008.07.038.
[5] Lutgens L, van der Zee J, Pijls-Johannesma M, et al. Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma[J]. Cochrane Database Syst Rev, 2010,(1):CD006377. DOI:10.1002/14651858. CD006377.pub2.
[6] Wittlinger M, Rödel CM, Weiss C, et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer:transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia[J]. Radiother Oncol, 2009, 93(2):358-363. DOI:10.1016/j.radonc.2009.09.018.
[7] Gani C, Schroeder C, Heinrich V, et al. Long-term local control and survival after preoperative radiochemotherapy in combination with deep regional hyperthermia in locally advanced rectal cancer[J]. Int J Hyperthermia, 2016, 32(2):187-192. DOI:10.3109/02656736.2015.1117661.
[8] Kim SW, Yea JW, Kim JH, et al. Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer[J]. Int J Clin Oncol, 2018, 23(2):287-297. DOI:10.1007/s10147-017-1213-z.
[9] Washington K. 7^th edition of the AJCC cancer staging manual:stomach[J]. Ann Surg Oncol, 2010, 17(12):3077-3079. DOI:10.1245/s10434-010-1362-z.
[10] Japanese Gastric Cancer Society. Japanese classification of gastric carcinoma[M]. 14^th ed. Tokyo:Jinyuan Publishing House, 2010. DOI:10.1007/s10120-011-0041-5.
[11] 王鑫, 金晶. 晚期胃癌的姑息性放疗价值研究回顾[J]. 中华放射肿瘤学杂志, 2016, 25(1):85-89. DOI:10.3760/cma.j.issn.1004-4221.2016.01.021.
Wang X, Jin J. Research progress in palliative radiotherapy for advanced gastric cancer[J]. Chin J Radiat Oncol, 2016, 25(1):85-89. DOI:10.3760/cma.j.issn.1004-4221.2016.01.021.
[12] Minn AY, Hsu A, La T, et al. Comparison of intensity-modulated radioth-erapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer[J]. Cancer, 2010, 116(16):3943-3952. DOI:10.1002/cncr.25246.
[13] Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastriccancer[J]. J Clin Oncol, 2011, 29(33):4387-4393. DOI:10.1200/JCO.2011.36.5908.
[14] Lee J, Lim DH, Kim S, et al. Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:the ARTIST trial[J]. J Clin Oncol, 2012, 30(3):268-273. DOI:10.1200/JCO.2011.39.1953.
[15] Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):a phase 3 open-label, randomised controlled trial[J]. Lancet, 2012, 379(9813):315-321. DOI:10.1016/S0140-6736(11)61873-4.
[16] Lee JL, Kang YK, Kang HJ, et al. A randomised multicentre phase Ⅱ trial of capecitabine vs. S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J]. Br J Cancer, 2008, 99(4):584-590. DOI:10.1038/sj.bjc.6604536.
[17] Perez CA, Pajak T, Emami B, et al. Randomized phase Ⅲ study comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors. Final report by the Radiation Therapy Oncology Group[J]. Am J Clin Oncol, 1991, 14(2):133-141. DOI:10.1097/00000421-199104000-00008.
[18] Song CW, Park H, Griffin RJ. Improvement of tumor oxygenation by mild hyperthermia[J]. Radiat Res, 2001, 155(4):515-528. DOI:10.1667/0033-7587(2001)155[0515:iotobm]2.0.co;2.
[19] Crezee H, van Leeuwen CM, Oei AL, et al. Thermoradiotherapy planning:integration in routine clinical practice[J]. Int J Hyperthermia, 2016, 32(1):41-49. DOI:10.3109/02656736.2015.1110757.
[20] Peeken JC, Vaupel P, Combs SE. Integrating hyperthermia into modern radiation oncology:what evidence is necessary?[J]. Front Oncol, 2017, 7(1):132. DOI:10.3389/fonc.2017.00132.